DOCSLIB.ORG

Citi Pure Low Risk Europe Long Short TR Index (CIISLRET)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Date: 20-Aug-21 Index Weights as of monthly rebalance date 10-Aug-21 Citi Pure Low Risk Europe Long Short TR Index (CIISLRET) Long Exposure Short Exposure Constituent Bloomberg Ticker Constituent Name Weight(%) Constituent Bloomberg Ticker Constituent Name Weight(%) 1 ABN NA Equity ABN AMRO Group NV 0.53% 1 1COV GY Equity Covestro AG -0.51% 2 AENA SQ Equity AENA SA 0.07% 2 AAL LN Equity Anglo American Plc -0.80% 3 AGN NA Equity Aegon NV 1.40% 3 ABBN SE Equity ABB LTD-REG -0.95% 4 AD NA Equity Ahold NV 1.01% 4 ABF LN Equity Associated British Foods -0.56% 5 AI FP Equity Air Liquide 1.05% 5 ABI BB Equity Anheuser Busch Inbev NV -1.72% 6 AKE FP Equity Arkema 0.01% 6 AC FP Equity Accor -0.32% 7 AKZA NA Equity AKZO NOBEL NV EUR0.50(POST REV SPLIT) 0.13% 7 ACA FP Equity Credit Agricole SA -1.56% 8 ALC SE Equity ALCON AG CHF0.04 0.17% 8 ADEN SE Equity ADECCO GROUP AG-REG -0.23% 9 ALV GY Equity Allianz SE 0.46% 9 ADS GY Equity Adidas AG -1.37% 10 VNA GY Equity Deutsche Annington Immobilien 0.55% 10 ADYEN NA Equity Adyen NV -0.92% 11 ASM NA Equity ASM Intl 0.12% 11 AHT LN Equity Ashtead Group -0.29% 12 ASSAB SS Equity Assa Abloy B 0.89% 12 ALFA SS Equity Alfa Laval AB -1.26% 13 ATCOA SS Equity Atlas Copco AB A 0.09% 13 AMP IM Equity Amplifon SpA -0.45% 14 ATO FP Equity AtoS 1.65% 14 AMS SQ Equity Amadeus IT Hldg SA -0.09% 15 AV/ LN Equity Aviva 0.42% 15 ANTO LN Equity Antofagasta Hldgs -0.54% 16 BA/ LN Equity BAE Systems Plc 0.32% 16 ASML NA Equity ASML Holding NV -0.91% 17 BAER SE Equity JULIUS BAER GROUP LTD 0.10% 17 AZN LN Equity AstraZeneca Plc -0.03% 18 BARC LN Equity Barclays 0.07% 18 BAYN GY Equity Bayer AG -1.34% 19 BATS LN Equity British American Tobacco Plc 0.37% 19 BBVA SQ Equity Banco Bilbao Vizcaya Argentaria SA -0.01% 20 BEI GY Equity Beiersdorf AG 1.13% 20 BHP LN Equity BHP GROUP PLC ORD USD0.50 -0.31% 21 BMW GY Equity Bayer Motoren Werke AG (BMW) 0.13% 21 BN FP Equity Danone -0.52% 22 BNR GY Equity Brenntag AG 1.27% 22 BNP FP Equity BNP Paribas -1.74% 23 BOL SS Equity BOLIDEN AB NPV 0.61% 23 BVI FP Equity Bureau Veritas SA -0.51% 24 BP/ LN Equity BP 0.54% 24 CABK SQ Equity CaixaBank -0.13% 25 BRBY LN Equity Burberry Group 0.31% 25 CBK GY Equity Commerzbank AG -1.07% 26 BT/A LN Equity BT Group 0.13% 26 CCH LN Equity COCA-COLA HBC AG ORD CHF6.70 (CDI) -0.96% 27 CA FP Equity Carrefour SA 2.02% 27 CFR SE Equity CIE FINANCIERE RICHEMONT-REG -0.69% 28 CAP FP Equity Cap Gemini SA 0.23% 28 CLNX SQ Equity Cellnex Telecom SA -0.66% 29 CARLB DC Equity Carlsberg AS B 0.31% 29 CON GY Equity Continental AG -0.28% 30 COLOB DC Equity Coloplast AS B 1.29% 30 CRH ID Equity CRH ORD EUR0.32 -0.28% 31 CPG LN Equity Compass Group 0.01% 31 CSGN SE Equity CREDIT SUISSE GROUP AG-REG -0.73% 32 CPR IM Equity Davide Campari Group Milano SpA 0.12% 32 DBK GY Equity Deutsche Bank AG -1.30% 33 CRDA LN Equity Croda Intl 1.22% 33 ORSTED DC Equity Orsted A/S -0.60% 34 DANSKE DC Equity Danske Bank A/S 0.38% 34 DGE LN Equity Diageo Plc -0.44% 35 DB1 GY Equity Deutsche Boerse AG 1.29% 35 DHER GY Equity DELIVERY HERO AG -0.52% 36 DIM FP Equity Sartorius Stedim Biotech 0.90% 36 DSM NA Equity Koninklijke DSM NV -0.47% 37 DPW GY Equity Deutsche Post AG 0.36% 37 DSV DC Equity Dsv A/S -0.02% 38 DSY FP Equity DASSAULT SYSTEMES EUR0.10 (POST SUBDIVISION) 1.05% 38 AIR FP Equity EADS NV-Euro Aero Defense -2.25% 39 DTE GY Equity Deutsche Telekom 0.08% 39 EBS AV Equity Erste Group Bank AG -0.17% 40 DWNI GY Equity Deutsche Wohnen AG BR 1.16% 40 EDEN FP Equity Edenred -0.29% 41 EDP PL Equity Electricidade de Portugal SA 0.17% 41 EDF FP Equity Electricite de France -0.49% 42 ELUXB SS Equity Electrolux AB B 0.75% 42 ELE SQ Equity Endesa SA -0.32% 43 EN FP Equity Bouygues 0.87% 43 ENEL IM Equity Enel SpA -0.08% 44 ENI IM Equity ENI SpA 0.71% 44 EO FP Equity Faurecia -1.09% 45 ENR GY Equity Siemens Energy AG 2.55% 45 ERF FP Equity EUROFINS SCIENTIFI EUR0.10 -0.16% 46 EOAN GY Equity E.ON AG 0.35% 46 EVK GY Equity Evonik Industries -0.57% 47 EQT SS Equity EQT AB 1.38% 47 EVO SS Equity Evolution Gaming Group AB -0.70% 48 ERICB SS Equity ERICSSON LM-B SHS 2.06% 48 FER SQ Equity Ferrovial SA -0.71% 49 ESSITYB SS Equity ESSITY AKTIEBOLAG-B 0.88% 49 FGR FP Equity Eiffage -1.18% 50 EXPN LN Equity Experian Plc 0.93% 50 FME GY Equity Fresenius Medical -1.28% 51 FBK IM Equity FinecoBank Banca Fineco SpA 0.53% 51 FR FP Equity Valeo -1.30% 52 TTE FP Equity TOTAL SA 0.29% 52 FRE GY Equity Fresenius SE & Co KGaA -1.38% 53 SGRE SQ Equity Gamesa Corp Tecnologica SA 0.60% 53 GMAB DC Equity Genmab AS -1.12% 54 GEBN SE Equity GEBERIT AG-REG 1.15% 54 GIVN SE Equity GIVAUDAN-REG -0.20% 55 ENT LN Equity GVC HLDGS PLC ORD EUR0.01 0.32% 55 GLE FP Equity Societe Generale -1.00% 56 HEI GY Equity HeidelbergCement AG 0.06% 56 GLEN LN Equity Glencore International PLC -1.57% 57 HEN3 GY Equity Henkel AG & Co. KGaA Nvtg Prf 0.12% 57 GN DC Equity GN Store Nord AS -0.51% 58 HFG GY Equity HelloFresh SE 1.32% 58 GSK LN Equity GlaxoSmithKline -0.73% 59 IBE SQ Equity Iberdrola SA 0.46% 59 ENGI FP Equity GDF Suez -1.51% 60 III LN Equity 3I Group 1.21% 60 HEIA NA Equity Heineken NV -1.03% 61 INVEB SS Equity INVESTOR AB SER'B'NPV 1.08% 61 HEXAB SS Equity HEXAGON AB SER'B'NPV -0.23% 62 ITRK LN Equity Intertek Group PLC 0.46% 62 HMB SS Equity Hennes & Mauritz AB B -1.67% 63 JMAT LN Equity JOHNSON MATTHEY PLC 0.38% 63 HO FP Equity Thales -0.23% 64 KBX GY Equity Knorr-Bremse AG 0.13% 64 IFX GY Equity Infineon Technologies AG -1.37% 65 KNEBV FH Equity Kone Corp B 0.93% 65 IHG LN Equity INTERCONTL HOTELS ORD GBP0.208521303 -0.80% 66 KPN NA Equity Koninklijke KPN NV 0.65% 66 ILD FP Equity ILIAD SA -0.70% 67 LR FP Equity Legrand Promesses 0.77% 67 IMB LN Equity Imperial Tobacco -0.19% 68 LSEG LN Equity London Stock Exchange Plc 1.82% 68 INF LN Equity INFORMA PLC ORD GBP0.001 -0.62% 69 ML FP Equity Michelin CGDE B Brown 0.70% 69 INGA NA Equity ING Groep NV -3.22% 70 MNDI LN Equity Mondi Plc 0.56% 70 ISP IM Equity Intesa SanPaolo -1.64% 71 MONC IM Equity MONCLER SPA 0.78% 71 ITX SQ Equity Inditex SA -0.99% 72 MRK GY Equity MERCK KGaA 0.45% 72 KER FP Equity PPR SA -0.23% 73 MRW LN Equity Morrison (WM) Supermarkets 0.37% 73 KINVB SS Equity KINNEVIK AB SER'B'NPV (POST SPLIT) -1.59% 74 MUV2 GY Equity Munich Re AG 0.31% 74 KNIN SE Equity KUEHNE + NAGEL INTL AG-REG -0.69% 75 NDA SS Equity NORDEA BANK ABP NPV 0.15% 75 KYGA ID Equity Kerry Group A -0.03% 76 NG/ LN Equity National Grid PLC 1.23% 76 LGEN LN Equity Legal & General Group -0.58% 77 NN NA Equity NN Group NV 1.92% 77 HOLN SE Equity LAFARGEHOLCIM LTD-REG -0.08% 78 NOKIA FH Equity Nokia OYJ 0.69% 78 LLOY LN Equity Lloyds Banking Group Plc -0.54% 79 NOVN SE Equity NOVARTIS AG-REG 0.05% 79 LOGN SE Equity Logitech International SA -0.73% 80 NOVOB DC Equity Novo Nordisk AS B 0.74% 80 LONN SE Equity LONZA GROUP AG-REG -0.59% 81 NZYMB DC Equity Novozymes AS B 0.49% 81 LUNE SS Equity Lundin Petroleum A -2.07% 82 OCDO LN Equity Ocado Group PLC 1.27% 82 MAERSKB DC Equity AP Moller - Maersk AS B -0.32% 83 OR FP Equity L'Oreal 1.45% 83 MB IM Equity Mediobanca SpA -0.14% 84 PAH3 GY Equity Porsche Automobil Holding SE 0.86% 84 MC FP Equity LVMH-Moet Vuitton -0.06% 85 PRX NA Equity Prosus NV 1.15% 85 MT NA Equity ArcelorMittal -0.60% 86 FLTR ID Equity PADDY POWER PLC 0.45% 86 MTX GY Equity MTU Aero Engines Holding AG -1.39% 87 QIA GY Equity QIAGEN AG 1.12% 87 NESTE FH Equity Neste Oil OYJ -0.27% 88 RACE IM Equity FERRARI NV 0.17% 88 NESN SE Equity NESTLE SA-REG -0.54% 89 RAND NA Equity Randstad Hldgs NV 0.52% 89 NHY NO Equity Norsk Hydro AS -1.04% 90 TEP FP Equity Teleperformance 0.84% 90 NXT LN Equity Next -1.87% 91 RDSA LN Equity Royal Dutch Shell PLC 0.13% 91 PGHN SE Equity PARTNERS GROUP HLG CHF0.01 (REGD) -0.96% 92 RDSB LN Equity Royal Dutch Shell PLC B 0.28% 92 PHIA NA Equity Koninklijke Philips Electronics NV (Royal Philips Electronics) -0.91% 93 REL LN Equity Reed Elsevier 0.27% 93 PNDORA DC Equity Pandora A/S -0.80% 94 REP SQ Equity Repsol-YPF SA 0.35% 94 PRY IM Equity Prysmian SpA -0.47% 95 RI FP Equity Pernod-Ricard 0.56% 95 PUB FP Equity Publicis Groupe -0.67% 96 RIO LN Equity Rio Tinto Plc 1.11% 96 PUM GY Equity PUMA SE -0.11% 97 RMS FP Equity Hermes Intl 2.60% 97 RKT LN Equity Reckitt Benckiser Group PLC -0.82% 98 RTO LN Equity Rentokil Initial 0.54% 98 NWG LN Equity ROYAL BANK OF SCOTLAND GROUP -0.62% 99 RWE GY Equity RWE AG 0.34% 99 REE SQ Equity Red Electrica Corporacion SA -0.05% 100 SAN FP Equity Sanofi-Aventis 1.55% 100 RNO FP Equity Renault SA -0.88% 101 SCHP SE Equity SCHINDLER HOLDING-PART CERT 0.66% 101 ROG SE Equity ROCHE HOLDING AG-GENUSSCHEIN -0.62% 102 SCMN SE Equity SWISSCOM AG-REG 0.21% 102 RR/ LN Equity Rolls-Royce Holdings Plc -2.03% 103 SGE LN Equity Sage Group 1.35% 103 SAF FP Equity Safran SA -1.62% 104 SGO FP Equity COMPAGNIE DE SAINT-GOBAIN 0.60% 104 SAMPO FH Equity Sampo Oyj A -1.24% 105 SGRO LN Equity SEGRO Plc 0.31% 105 SAND SS Equity Sandvik AB -0.10% 106 SHBA SS Equity Svenska Handelsbanken A 1.09% 106 SAP GY Equity SAP AG -0.57% 107 SHL GY Equity Siemens Healthineers AG 1.66% 107 SEBA SS Equity SEB-Skand Enskilda Banken A -0.28% 108 SLHN SE Equity SWISS LIFE HOLDING AG-REG 0.79% 108 SGSN SE Equity SGS SA-REG -0.38% 109 SOLB BB Equity Solvay 0.02% 109 SIE GY Equity Siemens AG -1.06% 110 SREN SE Equity SWISS RE AG 1.41% 110 SIKA SE Equity SIKA AG-BR -0.14% 111 SRG IM Equity Snam Rete Gas SpA 0.30% 111 SKFB SS Equity SKF AB B -0.67% 112 SRT3 GY Equity Sartorius AG Nvtg Prf 0.69% 112 SKG ID Equity SMURFIT KAPPA GRP ORD EUR0.001 -0.14% 113 SU FP Equity Schneider Electric SA 1.17% 113 SN/ LN Equity Smith & Nephew -0.13% 114 SW FP Equity Sodexo
Recommended publications
  • DWS (CH) II Small and Mid Caps Switzerland

    DWS (CH) II Small and Mid Caps Switzerland

    Marketing Material DWS (CH) II Small and Mid Caps Switzerland Equity Funds - Europe - Regions/Countries August 2021 As at 31/08/2021 Fund Data Performance Investment Policy Performance - Share Class FD (in %) The goal of the sub-fund is primarily to achieve long-term growth in Swiss Francs through investment in a portfolio of stocks from Swiss issuers that are listed in a representative Swiss equities index of small and medium enterprises or the small and mid- cap subindex of a Swiss equities index (“the benchmark”). The investment strategy is based on a transparent and comprehensible investment process, focuses on stock selection. Fund Benchmark (since 09/08/2006): SPI EXTRA Total Return (RI) Past performance is no indication of current or future performance, and the performance data do not take account of the commissions and costs Fund Management's Comment incurred on the issue and redemption of units. For detailed comments on the fund and its corresponding markets please see the annual report. Cumulative performance (in %) - share class FD 1 m 1 y 3 y 5 y s. Inception YTD 3 y avg 5 y avg 2017 2018 2019 2020 CHF 3.0 42.7 36.1 77.7 421.8 29.6 10.8 12.2 29.9 -21.6 29.3 1.8 EUR 2.7 42.0 42.2 80.2 650.5 30.2 12.5 12.5 19.4 -18.6 33.7 2.2 BM IN CHF 2.5 34.9 39.1 90.5 284.2 23.7 11.6 13.8 29.7 -17.2 30.4 8.1 Further Characteristics (3 years) / VAR (1 year) - share class FD Volatility 18.36% Maximum Drawdown -21.26% VAR (99%/10 days) 7.23% Sharpe Ratio -- Information Ratio -0.16 Correlation Coefficient 0.97 Alpha -1.26% Beta 1.05 Tracking Error
  • Heidelbergcement Half-Year Financial Report January to June

    Heidelbergcement Half-Year Financial Report January to June

    Half-Year Financial Report January to June 2020 HeidelbergCement achieves good half-year results for 2020 in challenging environment Weak demand due to coronavirus in second quarter – revenue decreases by 10% in first half of 2020 COPE action plan with high cost savings and preservation of liquidity – result 1) declines only slightly by 2% in the first half of 2020 Group share of net result for the period reduced by non-recurring effect from impairments – adjusted Group share rises by 5% Free cash flow at a strong level – net debt decreases by €1.4 billion Solid start into third quarter but business prospects for second half of 2020 remain uncertain – long-term outlook positive 1) Result from current operations before depreciation and amortisation Overview January to June 2020 January - June €m 2019 1) 2020 Revenue 9,212 8,254 Result from equity accounted investments (REI) 126 98 Result from current operations before depreciation and amortisation (RCOBD) 1) 1,438 1,404 RCOBD margin in % 15.6% 17.0% Result from current operations 1) 754 710 Additional ordinary result -128 -3,490 Earnings before interest and taxes (EBIT) 1) 626 -2,779 Financial result 1) -176 -157 Profit / loss before tax 450 -2,936 Net income / loss from continuing operations 300 -3,075 Net loss from discontinued operations -9 -20 Profit / loss for the period 291 -3,095 Group share of profit / loss 212 -3,133 Investments 501 458 1) Changed due to reclassifications Due to rounding, numbers presented in the Half-Year Financial Report may not add up precisely to the totals provided.
  • Liste Des Actions Concernées Par L'interdiction De Positions Courtes Nettes

    Liste Des Actions Concernées Par L'interdiction De Positions Courtes Nettes

    Liste des actions concernées par l'interdiction de positions courtes nettes L’interdiction s’applique aux actions listées sur une plate-forme française et relevant de la compétence de l’AMF au titre du règlement 236/2012 (information disponible dans les registres ESMA). Cette liste est fournie à titre informatif. L'AMF n'est pas en mesure de garantir que le contenu disponible est complet, exact ou à jour. Compte tenu des diverses sources de données sous- jacentes, des modifications pourraient être apportées régulièrement. Isin Nom FR0010285965 1000MERCIS FR0013341781 2CRSI FR0010050773 A TOUTE VITESSE FR0000076887 A.S.T. GROUPE FR0010557264 AB SCIENCE FR0004040608 ABC ARBITRAGE FR0013185857 ABEO FR0012616852 ABIONYX PHARMA FR0012333284 ABIVAX FR0000064602 ACANTHE DEV. FR0000120404 ACCOR FR0010493510 ACHETER-LOUER.FR FR0000076861 ACTEOS FR0000076655 ACTIA GROUP FR0011038348 ACTIPLAY (GROUPE) FR0010979377 ACTIVIUM GROUP FR0000053076 ADA BE0974269012 ADC SIIC FR0013284627 ADEUNIS FR0000062978 ADL PARTNER FR0011184241 ADOCIA FR0013247244 ADOMOS FR0010340141 ADP FR0010457531 ADTHINK FR0012821890 ADUX FR0004152874 ADVENIS FR0013296746 ADVICENNE FR0000053043 ADVINI US00774B2088 AERKOMM INC FR0011908045 AG3I ES0105422002 AGARTHA REAL EST FR0013452281 AGRIPOWER FR0010641449 AGROGENERATION CH0008853209 AGTA RECORD FR0000031122 AIR FRANCE -KLM FR0000120073 AIR LIQUIDE FR0013285103 AIR MARINE NL0000235190 AIRBUS FR0004180537 AKKA TECHNOLOGIES FR0000053027 AKWEL FR0000060402 ALBIOMA FR0013258662 ALD FR0000054652 ALES GROUPE FR0000053324 ALPES (COMPAGNIE)
  • Annual Report 2004

    Annual Report 2004

    ANNUAL REPORT 2004 CONTENTS 2 Company Overview HYGIENE Hygiene Services offers a total washroom solution service, 4 Chairman’s Statement floor mat, garments and flat linen rental services. The 6 Chief Executive’s Review washroom solutions range provides every consumable item, 13 Finance Director’s Review dispensers, drying and disposal systems required in today’s modern washroom. Protective floor mats are supplied to a 19 Directors and Secretary wide client base. Bespoke workwear is manufactured and 20 Report of the Directors supplied to commercial, industrial and hospitality customers, 27 Audit Committee Report with full inventory management available, and specialist high-performance workwear is designed and produced for 30 Remuneration Report sectors such as the medical, hi-tech and emergency 41 Statement of Directors’ services. Flat linen (primarily table and bedroom linen) Responsibilities is rented and laundered for corporate and hospitality customers and health service providers. 42 Report of the Auditors 44 Consolidated Profit and Pest Control provides a service for the prevention of pests, Loss Account primarily in the commercial and industrial sectors. Our research and development provides effective and innovative 45 Statement of Total Recognised solutions for pest control with specific emphasis placed on Gains and Losses health, safety and protection of the environment. 45 Reconciliation of Movements SECURITY in Equity Shareholders’ Funds Security delivers solutions that meet customers’ needs for 46 Balance Sheets personal safety and protection of property. We provide 47 Consolidated Cash Flow Statement security services for our customers tailored to meet their individual requirements, using advanced electronic security 48 Accounting Policies technology, well trained security officers or a combination 51 Notes to the Accounts of both services.
  • Corporate Governance

    Corporate Governance

    Business report Corporate governance Transparency is one of the key elements of good corporate governance, to which Sonova is committed. Good corporate governance is essential for Sonova and we strive for high standards in this field. What “good corporate governance” means is an evolving matter and we constantly monitor the latest changes to the requirements. Compliance is an integral element of our corporate culture and embedded in our core values. We therefore continued to strengthen the Sonova Group compliance program during the 2017/18 financial year, putting particular emphasis on integrating our acquired businesses into our compliance culture, designing new global compliance training, and updating our antibribery policy. Our continuing compliance efforts help us to live our values of ethical behavior and unquestionable integrity. At Sonova, corporate governance is based upon, and structured to conform with, relevant standards and practices. The company fulfils its legal duties under the Swiss Code of Obligations, the SIX Swiss Exchange Directive on Information relating to Corporate Governance, and the standards defined in the Swiss Code of Best Practice for Corporate Governance. This report describes the principles of corporate governance for the Sonova Group and provides background information on the Group’s executive officers and bodies as of March 31, 2018. All relevant documents can be accessed at the corporate governance section of the Sonova website: www.sonova.com/en/commitments/corporategovernance. For clarity and transparency, the compensation report is presented as a separate chapter of the annual report. Sonova Annual Report 2017/18 37 CORPORATE GOVERNANCE Group structure Operational group structure The Sonova Group is headquartered in Stäfa, Switzerland, and is active in over 100 countries.
  • Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)

    Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)

    Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation
  • Genmab Announces Data to Be Presented at 2017 ASCO Annual Meeting

    Genmab Announces Data to Be Presented at 2017 ASCO Annual Meeting

    Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting Media Release 8 abstracts on Genmab programs scheduled for presentation at ASCO Two daratumumab oral presentations and five daratumumab poster presentations Copenhagen, Denmark; April 20, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6. These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO website with the full abstracts scheduled to be published on May 17, 2017. “We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO conference,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. List of abstracts: Daratumumab: Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or
  • Annual Report 2018 19 Table of Content

    Annual Report 2018 19 Table of Content

    FINANCIAL REPORT Annual Report 2018 19 Table of content Letter to shareholders 2 Our product and service offering 6 Strategy and businesses 10 Corporate governance 36 Compensation report 60 Financial review 96 5 year key figures 104 Consolidated financial statements 105 Financial statements of Sonova Holding AG 175 Investor information 188 Corporate Responsibility Report 190 Letter to shareholders Dear shareholders, 2018/19 marked another year of solid financial performance, posting further record levels of sales and profits to which all three businesses contributed. Moreover – and as expected – growth accelerated from the first half-year to the second, driven by the launch of a number of innovative products and solutions. Sonova affirmed its leading position in audiological performance with the release of the Marvel™ technology platform. Marvel takes full advantage of the unique connectivity enabled by our SWORD™ (Sonova Wireless One Radio Digital) chip and combines it with the proven convenience of our rechargeable solutions. We also made significant progress in our retail business, which we have renamed “audiological care” for one simple reason: care is what we deliver. The expert service We have made significant provided by our hearing care professionals adds key value for the consumer. progress in implementing our strategy. Our cochlear implants business launched a series of innovative new products to strengthen its leading position in this expanding market. Robert Spoerry You will find details of these and other strategic initiatives in the “strategy and businesses” section of this report. The global market in which we operate is poised for further growth, as developed countries see increasing demand from the “baby boomer” generation and developing countries begin to bridge the gap in hearing care provision.
  • Annual Report 2018

    Annual Report 2018

    Rentokil Initial plc plc Initial Rentokil Protecting People Enhancing Lives... Annual Report 2018 Everywhere Annual Report 2018 About us Strong financial performance Rentokil Initial is a global leader in the provision of route-based services which Ongoing Revenue (at CER) protect people and enhance lives, everywhere. We operate in 90 of the world’s 100 leading cities – from Los Angeles to Amsterdam, and Singapore to Auckland. m Our core services are Pest Control and Hygiene and we offer a range of smaller £2,493.0 specialist services including Plants, Property Care and Workwear. We are a +13.2% multi-local business operating in 75 countries around the world, employing around 39,500 people in 2018. Organic Revenue growth What we do +3.7% Revenue (at AER) £2,472.3m +2.5% Ongoing Operating Profit (at CER) Pest Control Hygiene Protect & Enhance Pest Control as % Hygiene as % Protect & Enhance as % £333.6m of Group Revenue of Group Revenue of Group Revenue +13.3% Loss before income tax (at AER) 63% 22% 15% £114.1m -116.0% Free Cash Flow (at AER) £192.0m Where we are +94.2% cash conversion 2018 full year dividend 4.471p +15.2% Our RIGHT WAY plan Our RIGHT WAY plan divides our business into five geographic regions and three core categories, all operating on a low cost, single country operating structure. Since 2014 we have consistently implemented an effective strategy at pace and this has delivered consistent progress against our financial targets. North America UK & Rest of World Pacific We are now a stronger and more focused business, operating in higher growth Europe* Asia markets, with improving levels of organic *Includes our Latin America operations, managed and reported within our Europe region growth, reduced capital intensity and high levels of cash generation.
  • Genmab's 2020 Capital Markets

    Genmab's 2020 Capital Markets

    WELCOME Genmab’s 2020 Capital Markets Day November 13, 2020 Webcast Live from Utrecht and Princeton Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors.
  • Actions Synthétiques France Heures De Négociation : 9:00 - 17:30 (CET) Frais Et Commissions : 0.1% Du Montant De La Transaction, Min

    Actions Synthétiques France Heures De Négociation : 9:00 - 17:30 (CET) Frais Et Commissions : 0.1% Du Montant De La Transaction, Min

    Actions Synthétiques France Heures de négociation : 9:00 - 17:30 (CET) Frais et Commissions : 0.1% du montant de la transaction, min. 8 EUR (Marge sur commission: 70% - 99.9%). Symbole Instrument dont le prix est basé sur Nombre d'actions par lot Taille minimale d'un ordre en lots Vente à découvert Taux d'emprunt de titre (%) AC.FR Accor SA CFD 1 1 OUI -3 ACA.FR Credit Agricole SA CFD 1 1 OUI -3 ADP.FR Aeroports de Paris CFD 1 1 OUI -3 AF.FR Air France-KLM CFD 1 1 OUI -3 AI.FR Air Liquide SA CFD 1 1 OUI -3 AIR.FR Airbus Group NV CFD 1 1 NON - AKE.FR Arkema SA CFD 1 1 OUI -3 ALO.FR Alstom SA CFD 1 1 OUI -3 ALT.FR Altran Technologies SA CFD 1 1 OUI -3 ATO.FR AtoS CFD 1 1 OUI -3 BB.FR Societe BIC SA CFD 1 1 OUI -3 BIM.FR BioMerieux CFD 1 1 OUI -3 BN.FR Danone CFD 1 1 OUI -3 BNP.FR BNP Paribas CFD 1 1 OUI -3 BOL.FR Bollore SA CFD 1 1 OUI -3 BVI.FR Bureau Veritas SA CFD 1 1 OUI -3 CA.FR Carrefour SA CFD 1 1 OUI -3 CAP.FR Cap Gemini SA CFD 1 1 OUI -3 CGG.FR CGG SA CFD 1 1 NON - CNP.FR CNP Assurances CFD 1 1 OUI -3 CO.FR Casino Guichard Perrachon SA CFD 1 1 OUI -3 COFA.FR Coface SA CFD 1 1 OUI -4,5 CS.FR AXA SA CFD 1 1 OUI -3 DEC.FR JCDecaux SA CFD 1 1 OUI -3 DG.FR Vinci SA CFD 1 1 OUI -3 DSY.FR Dassault Systemes CFD 1 1 OUI -3 EDEN.FR Edenred CFD 1 1 OUI -3 EDF.FR EDF SA CFD 1 1 OUI -3 EI.FR Essilor International SA CFD 1 1 OUI -3 ELE.FR Euler Hermes Group CFD 1 1 OUI -4,5 EN.FR Bouygues SA CFD 1 1 OUI -3 ENGI.FR ENGIE CFD 1 1 OUI -3 ENX.FR Euronext NV CFD 1 1 OUI -3 EO.FR Faurecia CFD 1 1 OUI -3 ERA.FR Eramet CFD 1 1 OUI -5 ERF.FR Eurofins
  • Factset-Top Ten-0521.Xlsm

    Factset-Top Ten-0521.Xlsm

    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.